JP2019529516A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529516A5 JP2019529516A5 JP2019518286A JP2019518286A JP2019529516A5 JP 2019529516 A5 JP2019529516 A5 JP 2019529516A5 JP 2019518286 A JP2019518286 A JP 2019518286A JP 2019518286 A JP2019518286 A JP 2019518286A JP 2019529516 A5 JP2019529516 A5 JP 2019529516A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- compound
- syndrome
- disorder
- myopathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 43
- 201000010099 disease Diseases 0.000 claims description 21
- 208000035475 disorder Diseases 0.000 claims description 20
- 201000009623 Myopathy Diseases 0.000 claims description 14
- 208000021642 Muscular disease Diseases 0.000 claims description 12
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 12
- 230000007812 deficiency Effects 0.000 claims description 10
- 210000003205 muscle Anatomy 0.000 claims description 10
- 201000006938 muscular dystrophy Diseases 0.000 claims description 9
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 8
- 208000004350 Strabismus Diseases 0.000 claims description 7
- 230000003387 muscular Effects 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 6
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 208000002780 macular degeneration Diseases 0.000 claims description 6
- 201000000585 muscular atrophy Diseases 0.000 claims description 6
- 230000000750 progressive effect Effects 0.000 claims description 6
- 208000001076 sarcopenia Diseases 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 108010015181 PPAR delta Proteins 0.000 claims description 5
- 206010033799 Paralysis Diseases 0.000 claims description 5
- 201000008383 nephritis Diseases 0.000 claims description 5
- 208000019553 vascular disease Diseases 0.000 claims description 5
- 108010001058 Acyl-CoA Dehydrogenase Proteins 0.000 claims description 4
- 102000002735 Acyl-CoA Dehydrogenase Human genes 0.000 claims description 4
- 206010003694 Atrophy Diseases 0.000 claims description 4
- 108010068197 Butyryl-CoA Dehydrogenase Proteins 0.000 claims description 4
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 claims description 4
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 claims description 4
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 206010020961 Hypocholesterolaemia Diseases 0.000 claims description 4
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 claims description 4
- 108010027062 Long-Chain Acyl-CoA Dehydrogenase Proteins 0.000 claims description 4
- 102000018653 Long-Chain Acyl-CoA Dehydrogenase Human genes 0.000 claims description 4
- 206010028289 Muscle atrophy Diseases 0.000 claims description 4
- 206010028372 Muscular weakness Diseases 0.000 claims description 4
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 4
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 4
- 230000037444 atrophy Effects 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000020411 cell activation Effects 0.000 claims description 4
- 208000030533 eye disease Diseases 0.000 claims description 4
- 208000030175 lameness Diseases 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 4
- 208000012268 mitochondrial disease Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 230000020763 muscle atrophy Effects 0.000 claims description 4
- 210000002569 neuron Anatomy 0.000 claims description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 3
- 208000014245 Ocular vascular disease Diseases 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 206010030875 ophthalmoplegia Diseases 0.000 claims description 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims description 2
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims description 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims description 2
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 101710147349 Carnitine transporter Proteins 0.000 claims description 2
- 208000015374 Central core disease Diseases 0.000 claims description 2
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 2
- 206010060774 Chondrosis Diseases 0.000 claims description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 2
- 201000000915 Chronic Progressive External Ophthalmoplegia Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010010356 Congenital anomaly Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 2
- 208000016192 Demyelinating disease Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 208000002249 Diabetes Complications Diseases 0.000 claims description 2
- 206010012655 Diabetic complications Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims description 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 208000032843 Hemorrhage Diseases 0.000 claims description 2
- 101000841267 Homo sapiens Long chain 3-hydroxyacyl-CoA dehydrogenase Proteins 0.000 claims description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 206010020740 Hyperproteinaemia Diseases 0.000 claims description 2
- 208000034767 Hypoproteinaemia Diseases 0.000 claims description 2
- 208000029400 Inclusion myopathy Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 206010022489 Insulin Resistance Diseases 0.000 claims description 2
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 2
- 102100029107 Long chain 3-hydroxyacyl-CoA dehydrogenase Human genes 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000035177 MELAS Diseases 0.000 claims description 2
- 208000035172 MERRF Diseases 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims description 2
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims description 2
- 208000010428 Muscle Weakness Diseases 0.000 claims description 2
- 206010049565 Muscle fatigue Diseases 0.000 claims description 2
- 208000021908 Myocardial disease Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 208000013234 Pearson syndrome Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000037111 Retinal Hemorrhage Diseases 0.000 claims description 2
- 201000007737 Retinal degeneration Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 206010038926 Retinopathy hypertensive Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 108010052164 Sodium Channels Proteins 0.000 claims description 2
- 102000018674 Sodium Channels Human genes 0.000 claims description 2
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 206010059790 Ulnar nerve palsy Diseases 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 230000001919 adrenal effect Effects 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 208000021328 arterial occlusion Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000009310 astigmatism Diseases 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 201000007303 central core myopathy Diseases 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 206010010121 compartment syndrome Diseases 0.000 claims description 2
- 208000016097 disease of metabolism Diseases 0.000 claims description 2
- 201000009338 distal myopathy Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 210000004709 eyebrow Anatomy 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 210000004276 hyalin Anatomy 0.000 claims description 2
- 201000001421 hyperglycemia Diseases 0.000 claims description 2
- 230000001631 hypertensive effect Effects 0.000 claims description 2
- 201000001948 hypertensive retinopathy Diseases 0.000 claims description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 2
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 208000006443 lactic acidosis Diseases 0.000 claims description 2
- 210000002429 large intestine Anatomy 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- 230000006372 lipid accumulation Effects 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 201000005296 lung carcinoma Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 206010025482 malaise Diseases 0.000 claims description 2
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 claims description 2
- 230000002438 mitochondrial effect Effects 0.000 claims description 2
- 150000004682 monohydrates Chemical class 0.000 claims description 2
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 2
- 230000036473 myasthenia Effects 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 208000001491 myopia Diseases 0.000 claims description 2
- 230000004379 myopia Effects 0.000 claims description 2
- 201000009925 nephrosclerosis Diseases 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 230000000926 neurological effect Effects 0.000 claims description 2
- 208000018360 neuromuscular disease Diseases 0.000 claims description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 208000021090 palsy Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 230000002085 persistent effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 201000001514 prostate carcinoma Diseases 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 230000004043 responsiveness Effects 0.000 claims description 2
- 229960002477 riboflavin Drugs 0.000 claims description 2
- 235000019192 riboflavin Nutrition 0.000 claims description 2
- 239000002151 riboflavin Substances 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 230000009759 skin aging Effects 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 208000036722 ulnar neuropathy Diseases 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000004438 eyesight Effects 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000009928 nephrosis Diseases 0.000 claims 1
- 231100001027 nephrosis Toxicity 0.000 claims 1
- 238000000034 method Methods 0.000 description 6
- 208000001692 Esotropia Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 101710108470 Hyalin Proteins 0.000 description 1
- 206010020675 Hypermetropia Diseases 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 206010002537 anisometropia Diseases 0.000 description 1
- 229910001651 emery Inorganic materials 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 201000006318 hyperopia Diseases 0.000 description 1
- 230000004305 hyperopia Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404474P | 2016-10-05 | 2016-10-05 | |
| US62/404,474 | 2016-10-05 | ||
| PCT/US2017/055403 WO2018067860A1 (en) | 2016-10-05 | 2017-10-05 | Crystalline and salt forms of ppar agonist compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529516A JP2019529516A (ja) | 2019-10-17 |
| JP2019529516A5 true JP2019529516A5 (https=) | 2020-10-22 |
| JP7017563B2 JP7017563B2 (ja) | 2022-02-08 |
Family
ID=60153508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518286A Active JP7017563B2 (ja) | 2016-10-05 | 2017-10-05 | Ｐｐａｒアゴニスト化合物の結晶性および塩形態 |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US10927094B2 (https=) |
| EP (1) | EP3523283B1 (https=) |
| JP (1) | JP7017563B2 (https=) |
| KR (1) | KR20190057129A (https=) |
| CN (1) | CN109843857B (https=) |
| AU (1) | AU2017340763B2 (https=) |
| CA (1) | CA3036587A1 (https=) |
| CO (1) | CO2019003162A2 (https=) |
| CY (1) | CY1124655T1 (https=) |
| DK (1) | DK3523283T3 (https=) |
| ES (1) | ES2887008T3 (https=) |
| HR (1) | HRP20211341T1 (https=) |
| HU (1) | HUE055678T2 (https=) |
| IL (1) | IL265730B (https=) |
| JO (1) | JOP20190039B1 (https=) |
| LT (1) | LT3523283T (https=) |
| MA (1) | MA46460A (https=) |
| MX (1) | MX385973B (https=) |
| MY (1) | MY202008A (https=) |
| PH (1) | PH12019500727A1 (https=) |
| PL (1) | PL3523283T3 (https=) |
| PT (1) | PT3523283T (https=) |
| RS (1) | RS62245B1 (https=) |
| RU (1) | RU2759724C2 (https=) |
| SG (1) | SG11201901995TA (https=) |
| SI (1) | SI3523283T1 (https=) |
| TW (1) | TWI769182B (https=) |
| UA (1) | UA124770C2 (https=) |
| WO (1) | WO2018067860A1 (https=) |
| ZA (1) | ZA201901744B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006249866B2 (en) | 2005-05-26 | 2011-10-13 | Aldeyra Therapeutics, Inc. | Compositions and methods of treating retinal disease |
| WO2011072141A1 (en) | 2009-12-11 | 2011-06-16 | Neuron Systems, Inc. | Compositions and methods for the treatment of macular degeneration |
| CN117045653A (zh) | 2013-01-23 | 2023-11-14 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
| US10550085B2 (en) | 2015-08-21 | 2020-02-04 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
| EA037371B1 (ru) * | 2015-10-07 | 2021-03-19 | Митобридж, Инк. | Агонисты ppar, соединения, фармацевтические композиции и способы их применения |
| ES2887008T3 (es) | 2016-10-05 | 2021-12-21 | Mitobridge Inc | Formas cristalinas y de sal de compuestos agonistas del PPAR |
| WO2019075136A1 (en) | 2017-10-10 | 2019-04-18 | Aldeyra Therapeutics, Inc. | TREATMENT OF INFLAMMATORY DISORDERS |
| AU2019319740A1 (en) * | 2018-08-06 | 2021-03-25 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| WO2020085393A1 (ja) | 2018-10-23 | 2020-04-30 | 国立研究開発法人科学技術振興機構 | ＰＰＡＲδ活性化剤 |
| JP2022530967A (ja) | 2019-05-02 | 2022-07-05 | アルデイラ セラピューティクス， インコーポレイテッド | 多形化合物およびその使用 |
| WO2020223717A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| WO2021231792A1 (en) | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| BR112023025221A2 (pt) | 2021-06-02 | 2024-02-27 | Astellas Pharma Inc | Métodos de uso de compostos agonistas de ppar e composições farmacêuticas dos mesmos |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
| WO2025207099A1 (en) * | 2024-03-28 | 2025-10-02 | Astellas Pharma Inc. | Ppar-delta inhibitors for preventing post-operative atrial fibrillation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7396850B2 (en) | 2003-01-06 | 2008-07-08 | Eli Lilly And Company | Pyrazole derivative as PPAR modulator |
| EP1671633A1 (en) * | 2004-12-17 | 2006-06-21 | Sanofi-Aventis Deutschland GmbH | Use of PPAR agonists for the treatment of congestive heart failure |
| AU2006210503B2 (en) * | 2005-02-03 | 2009-09-03 | Irm Llc | Compounds and compositions as PPAR modulators |
| CN101296892A (zh) * | 2005-09-07 | 2008-10-29 | 普莱希科公司 | Ppar活性化合物 |
| DE102006023336A1 (de) * | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
| FR2940289B1 (fr) * | 2008-12-23 | 2014-09-12 | Biopharmed | Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas |
| CN102727489A (zh) * | 2012-07-18 | 2012-10-17 | 西南大学 | 5-芳(杂环)亚甲基噻唑烷-2，4-二酮在制备ppar激动剂中的应用 |
| US20170305894A1 (en) * | 2014-10-08 | 2017-10-26 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| EA037371B1 (ru) | 2015-10-07 | 2021-03-19 | Митобридж, Инк. | Агонисты ppar, соединения, фармацевтические композиции и способы их применения |
| US11358954B2 (en) | 2016-04-13 | 2022-06-14 | Mitobridge, Inc. | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| ES2859487T3 (es) | 2016-10-05 | 2021-10-04 | Mitobridge Inc | Métodos para tratar las lesiones renales agudas |
| ES2887008T3 (es) | 2016-10-05 | 2021-12-21 | Mitobridge Inc | Formas cristalinas y de sal de compuestos agonistas del PPAR |
-
2017
- 2017-10-05 ES ES17787774T patent/ES2887008T3/es active Active
- 2017-10-05 PT PT177877743T patent/PT3523283T/pt unknown
- 2017-10-05 HU HUE17787774A patent/HUE055678T2/hu unknown
- 2017-10-05 AU AU2017340763A patent/AU2017340763B2/en active Active
- 2017-10-05 CA CA3036587A patent/CA3036587A1/en active Pending
- 2017-10-05 DK DK17787774.3T patent/DK3523283T3/da active
- 2017-10-05 HR HRP20211341TT patent/HRP20211341T1/hr unknown
- 2017-10-05 WO PCT/US2017/055403 patent/WO2018067860A1/en not_active Ceased
- 2017-10-05 KR KR1020197012668A patent/KR20190057129A/ko not_active Ceased
- 2017-10-05 UA UAA201903678A patent/UA124770C2/uk unknown
- 2017-10-05 SG SG11201901995TA patent/SG11201901995TA/en unknown
- 2017-10-05 PL PL17787774T patent/PL3523283T3/pl unknown
- 2017-10-05 MY MYPI2019001560A patent/MY202008A/en unknown
- 2017-10-05 US US16/334,746 patent/US10927094B2/en active Active
- 2017-10-05 RS RS20211042A patent/RS62245B1/sr unknown
- 2017-10-05 JO JOP/2019/0039A patent/JOP20190039B1/ar active
- 2017-10-05 EP EP17787774.3A patent/EP3523283B1/en active Active
- 2017-10-05 SI SI201730879T patent/SI3523283T1/sl unknown
- 2017-10-05 IL IL265730A patent/IL265730B/en unknown
- 2017-10-05 JP JP2019518286A patent/JP7017563B2/ja active Active
- 2017-10-05 TW TW106134298A patent/TWI769182B/zh active
- 2017-10-05 LT LTEPPCT/US2017/055403T patent/LT3523283T/lt unknown
- 2017-10-05 CN CN201780062034.5A patent/CN109843857B/zh active Active
- 2017-10-05 MX MX2019003945A patent/MX385973B/es unknown
- 2017-10-05 MA MA046460A patent/MA46460A/fr unknown
- 2017-10-05 RU RU2019110736A patent/RU2759724C2/ru active
-
2019
- 2019-03-20 ZA ZA2019/01744A patent/ZA201901744B/en unknown
- 2019-03-29 CO CONC2019/0003162A patent/CO2019003162A2/es unknown
- 2019-04-03 PH PH12019500727A patent/PH12019500727A1/en unknown
-
2021
- 2021-02-19 US US17/179,604 patent/US11530192B2/en active Active
- 2021-08-31 CY CY20211100775T patent/CY1124655T1/el unknown
-
2022
- 2022-12-16 US US18/082,847 patent/US11912681B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019529516A5 (https=) | ||
| RU2019110736A (ru) | Кристаллические и солевые формы соединений агонистов ppar | |
| JP2019511527A5 (https=) | ||
| RU2018137521A (ru) | Агонисты ppar, соединения, фармацевтические композиции и способы их применения | |
| JP2018508569A5 (https=) | ||
| JP2013516501A5 (https=) | ||
| JP2017522264A5 (https=) | ||
| JP5701308B2 (ja) | 新規血管漏出遮断剤 | |
| JP7474706B2 (ja) | ４－フェニル酪酸を含有する老視の治療または予防剤 | |
| Escandon et al. | The role of peroxisome proliferator-activated receptors in healthy and diseased eyes | |
| JP2021533154A5 (https=) | ||
| CN101796028A (zh) | 1-苯基-2-吡啶基烷醇的衍生物作为磷酸二酯酶抑制剂 | |
| JP2019534311A (ja) | 線維症の治療 | |
| JP5801324B2 (ja) | 緑内障及び高眼圧症の治療のためのシチコリン | |
| WO2020129964A1 (ja) | ウルソデオキシコール酸を含有する老視の治療または予防剤 | |
| AU2016256552A1 (en) | Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis | |
| CN112716952A (zh) | 纤维化病治疗剂 | |
| CN106692973A (zh) | 一种组合物及其用途、药物制剂 | |
| JP7038437B2 (ja) | 眼障害及び皮膚疾患の処置のための化合物、組成物、及び方法 | |
| US9504730B2 (en) | Method of achieving a thymosin beta 4 concentration in a human patient | |
| AU2015389862B2 (en) | Use of thia oxo compounds for lowering Apo C3 | |
| JP2018510855A (ja) | 眼疾患を処置するための組成物及び方法 | |
| CN112759515A (zh) | 一种新型FFA1和PPARα/γ/δ四重激动剂、其制备方法及其作为药物的用途 | |
| CN111377993A (zh) | 三萜类化合物的新用途 | |
| KR20160030206A (ko) | 사구체 질환을 치료하는데 사용하기 위한 로스마피모드 |